Protein Stability Analysis Market Size

Protein Stability Analysis Market Analysis

The protein stability analysis market is expected to register a CAGR of 3.5% during the forecast period.

COVID-19 had a significant impact on the protein stability analysis market in the initial phase since protein stability studies were conducted to assess the structure and nature of the COVID-19 virus to a great extent which helps gain a better understanding of the virus and supports the development of effective and efficient therapeutics. For instance, as per the article published in September 2022 in Stanford Medicine, elevated virus levels in the blood of COVID-19 patients in hospitals predicted the worsening of respiratory symptoms and suggest ongoing viral replication in advanced disease stages. A protein of the virus that causes COVID-19 was measured in the patient's blood during the test. Hence, such analysis showing the complications associated with COVID-19 through protein analysis will likely boost the market growth.

In the post-pandemic era, studies are still being conducted due to the emergence of different COVID-19 mutants. Since the beginning of the pandemic, the WHO has described eight variants of interest (VOIs), namely Epsilon, Zeta, Eta, Theta, Iota, Kappa, Lambda, and Mu. Currently, studies are being conducted to determine whether mutants of Omicron variants affect the virus's properties, speed of spreading, the severity of the associated disease, the performance of vaccines, or other public health and social measures and hence, the demand for protein analysis products is expected to increase. Another factor to account for are the Sars-COV-2 strains which are expected to have a positive impact on the market over the forecast period.

Factors such as rising research and development expenditure of pharmaceutical and biopharmaceutical companies, increasing proteomics and genomics research activities, and an increasing number of recombinant protein therapeutics and biologics are expected to drive the market growth over the forecast period since research studies require protein stability assessments to substantiate the results.

For instance, as per the EFPIA 2022 report, in 2021, Europe invested an estimated EUR 41,500 million (about USD 35,109 million) in pharmaceutical R&D. Thus, huge investments in R&D drive the growth of the protein stability analysis market during the forecast period. Furthermore, investments and financing in genomic research activities are projected to fuel the market as researchers seek opportunities in protein stability studies. For instance, in September 2022 NHGRI, part of the NIH, planned to fund USD 3.35 million over five years to launch the Genome Research Experiences to attract researchers into the Genomics Field to Enhance Diversity (GREAT) program. Moreover, in September 2022, a joint venture by the University of Western Australia and Proteomics International, which conducts vital work in medical, environmental, and agricultural testing of proteins received a funding of USD 2 million . The money is likely to enable the WA Proteomics Facility to upgrade its automated tools and staff, increasing output capacity to hundreds of samples.

As a result of the increase in pharmaceutical and biopharmaceutical companies' R&D expenditures, as well as the increase in the number of proteomics and genomics research activities, the protein stability analysis market is anticipated to witness growth over the forecast period. However, the high cost of protein stability analysis systems is expected to restrain the growth of this market to a certain extent.